Log in

NYSEAMERICAN:NNVCNanoViricides Stock Price, Forecast & News

$7.41
-0.17 (-2.24 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.31
Now: $7.41
$7.85
50-Day Range N/A
52-Week Range
$1.27
Now: $7.41
$19.20
Volume800,292 shs
Average Volume2.79 million shs
Market Capitalization$67.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as injectable and oral anti-influenza nanoviricide drug for H7N9, Bird Flu H5N1, other Highly Pathogenic Influenzas, Epidemic Influenzas, and Seasonal Influenzas; DengueCide, an anti-dengue nanoviricide which is in pre-clinical development; and HIVCide, an anti-human immunodeficiency virus drug candidate. It is also developing HerpeCide, a skin cream for the treatment of cold sores and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NNVC
Previous SymbolNYSEMKT:NNVC
CUSIPN/A
Phone+1-203-9376137

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees7
Market Cap$67.23 million
Next Earnings Date8/28/2020 (Estimated)
OptionableOptionable

Receive NNVC News and Ratings via Email

Sign-up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter.

NanoViricides (NYSEAMERICAN:NNVC) Frequently Asked Questions

When is NanoViricides' next earnings date?

NanoViricides is scheduled to release its next quarterly earnings announcement on Friday, August 28th 2020. View our earnings forecast for NanoViricides.

How were NanoViricides' earnings last quarter?

NanoViricides Inc (NYSEAMERICAN:NNVC) announced its quarterly earnings results on Tuesday, February, 19th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.08. View NanoViricides' earnings history.

When did NanoViricides' stock split? How did NanoViricides' stock split work?

NanoViricides shares reverse split on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.

Has NanoViricides been receiving favorable news coverage?

Media coverage about NNVC stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. NanoViricides earned a coverage optimism score of -3.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about NanoViricides.

Are investors shorting NanoViricides?

NanoViricides saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 259,600 shares, a decrease of 14.5% from the June 15th total of 303,800 shares. Based on an average daily trading volume, of 856,500 shares, the short-interest ratio is presently 0.3 days. Currently, 3.3% of the shares of the stock are sold short. View NanoViricides' Current Options Chain.

Who are some of NanoViricides' key competitors?

What other stocks do shareholders of NanoViricides own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Micron Technology (MU), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Domino's Pizza (DPZ), AbbVie (ABBV), Novavax (NVAX), Vaxart (VXRT) and NVIDIA (NVDA).

Who are NanoViricides' key executives?

NanoViricides' management team includes the following people:
  • Dr. Anil R. Diwan, Chairman, Pres & Sec. (Age 60)
  • Ms. Meeta R. Vyas SB, MBA, Chief Financial Officer (Age 60)
  • Dr. Eugene Seymour, Chief Exec. Officer Emeritus (Age 78)
  • Dr. Randall W. Barton Ph.D., Chief Scientific Officer & Chief Regulatory Officer (Age 72)
  • Dr. Irach B. Taraporewala, Consultant & Director (Age 63)

What is NanoViricides' stock symbol?

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

How do I buy shares of NanoViricides?

Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NanoViricides' stock price today?

One share of NNVC stock can currently be purchased for approximately $7.41.

How big of a company is NanoViricides?

NanoViricides has a market capitalization of $67.23 million. NanoViricides employs 7 workers across the globe.

What is NanoViricides' official website?

The official website for NanoViricides is www.nanoviricides.com.

How can I contact NanoViricides?

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.